ࡱ> Root Entry''FileHeaderaDocInfoTHwpSummaryInformation.L) !"#$%'(*+,-.Root Entryʏ<' 'FileHeaderaDocInfoTHwpSummaryInformation.L &/012345 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKMNOPQRSUVWXYZ[\]^_`ebcdfgijmnopqrstvwxyz{|}~BodyText <'<'PrvImage PrvTextDocOptions ʏ<'ʏ<'Section0u` Scripts ʏ<'ʏ<'JScriptVersion k DefaultJScripth_LinkDocl 8] <\><08@  p > <\Դ><Ischaemic heart disease is the predominant contributor to cardiovascular morbidity and mortality. Over the past decade, stem cell transplantation has emerged as a promising therapeutic strategy for acute or chronic ischaemic cardiomyopathy. Multiple candidate cell types have been used in preclinical animal models and in humans to repair or regenerate the injured heart, either directly or indirectly (through paracrine effects), including: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), neonatal cardiomyocytes, skeletal myoblasts (SKMs), endothelial progenitor cells, bone marrow mononuclear cells (BMMNCs), mesenchymal stem cells (MSCs) and, most recently, cardiac stem cells (CSCs). Although no consensus has emerged yet, the ideal cell type for the treatment of heart disease should: (a) improve heart function; (b) create healthy and functional cardiac muscle and vasculature, integrated into the host tissue; (c) be amenable to delivery by minimally inv>lGIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`ZgoU\mҤ__xK_+^xǐ#KLyaf~ylv em,u^`a|w5M[lܹ]fM5櫉_~ACgox&g;LKozȯ~>Cه/aҾWjNve 7D =(QgPtͷapg!D z߁=faI_2 Ҹn#x}g[RbG#dXXp,BFfIW+xދѹn_#pXc}_iQfd\ezfJ.WKFzgC>jF2J(j&誣?Vp霚NꢔzbzkeQn~:l>hԞzr%)`꺩w],ca[A.UNyi"Zkl~‹eVrJm:0è[%ޮۢǾp 'oUolW>,er34VƩ,An1o,g!Y7+{l2K賚'RaQuKb&Y_p[a m-ܤiVg侍9srݲⓎ;.7<67;{ϺFo{F^0rֹYM}c̰5bW8nFWH1Y;0}S+_<-x욠7 d~lPe"M)0{aV@kԫ~C?R}<`ڠcLQiMgCGlb ÖBvVÂc :Z j+\b ('-X۞ѐyscD&c1r*bzݑ[^qؕ3pj<SHPui~)Cª 9ˁwHKF:b1CtŪ;;E$}`\8i$%WL4QPd%e+il:(Hɵ-iBUpJBX6XR$Bguc)pBԁ h򵞅LfFhL(M$tL376]L3YTDx:̭I)Kz7xԑQTFy*Z(Z-Bx3Q,6ĔK*HHZ+d^_T+txjttU UXհ;CV>m~r*ӥ?ERPSI35-EZҬj-癞"_e?m^k()RRPa1Zdղ^Ed+G-'h*JkwF Vq- h~FW(˽*d Vwa pS=_%2N[wi ouk^WD)KF cE.V:8MB x1oe`YH*S3HP,:"v*z݁ˬTdrSEiOPz/40CWY13x+#O02A k왺@UpYE! 7~|ZR5=zU}1ER?rꕢ 2?cilLڿJҿٞ[l4ЎMj[ζn{MrNvMzη~N|!;>=so*`a``a`0x  T ` lxajou2010D 2 10| ”| $ 2:36:28jaeho8, 0, 0, 466 WIN32LEWindows_7@m @<'@V&mfxhki&E֤C&9 ay2B4k'ٵn Ho WKkSQ76$E)JDˢ ]GASq.R,\v%q}.](.t}s4ڹG|̜,!xv`=ם<<&-%MI|noZƹcU5J9b<>@UƧlL$ %TvW5: оhFT`Y!ԥՄ4WUqm0, ѠGb ]Ŀ1U$puX26"^;o1 P0%/N)VK8q N# g(3\=v: NpUOUd2/j3gjԝ'[ ǶSkßi^'gΔ؍q'w:Ll kuzn󠮝ɴ;+l8u]2NjcE{ igE;m`Itj7?,IқH}W}|,6IdR3'c2#1Gc2318̨Ϣ+}8V#jSӒ\Ŵ(~>0 "yAʭe)Ŗ,p1M} K(>nN261}A2HXwnC@9l$/9{>زmпNPo/!ȢqMd6@DT}сS1q2ĉEŁӂASnۛۜk%lȝ6ev8sI !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKMNOPQRSUVWXYZ[\]^_`ebcdfgijmnopqrstvwxyz{|}~BodyText g'@'PrvImage PrvTextDocOptions ''Section0u^ Scripts ''JScriptVersion k DefaultJScripth_LinkDocl 8] <\><08@ p > <\Դ><Ischaemic heart disease is the predominant contributor to cardiovascular morbidity and mortality. Over the past decade, stem cell transplantation has emerged as a promising therapeutic strategy for acute or chronic ischaemic cardiomyopathy. Multiple candidate cell types have been used in preclinical animal models and in humans to repair or regenerate the injured heart, either directly or indirectly (through paracrine effects), including: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), neonatal cardiomyocytes, skeletal myoblasts (SKMs), endothelial progenitor cells, bone marrow mononuclear cells (BMMNCs), mesenchymal stem cells (MSCs) and, most recently, cardiac stem cells (CSCs). Although no consensus has emerged yet, the ideal cell type for the treatment of heart disease should: (a) improve heart function; (b) create healthy and functional cardiac muscle and vasculature, integrated into the host tissue; (c) be amenable to delivery by minimally inva>lGIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`ZgoU\mҤ__xK_+^xǐ#KLyaf~ylv em,u^`a|w5 MiޡCNZ6ܮu&:hgG8=cIV7`cOc7h~CG8aҾWjNve I]2~Qmv| zIx8`d&n%G|2x8cBރnc}{QDcG"dXmQ6"d.> f)imPV6y.y_h7F(Y~j(F)z#~#trz'aNb)'‚e`j={\zz\r*,h+Nig̾9gN`i6zvo-9U*%.C:0Ezِƾ;sGpq ceX[쮹bf._ Gz*f)\,tvL,KRj--Wr(JȜmۉ+mdñLՏVqu Kvsb.M׋p꫉XۓjZv=t%wEJ oQBep:T5;R_;5dj0P~'WVEHZd)66~3\Z*/7qFcmI HFu>QK]^xbӛiH!n];/~;F^hW}o. T["%ŮSz-pv,%8d3Y o-ٛRjI9`Z}OAmXi8nL 9˹,qFc3Yǎoa)1u 43ȅ[F? STeF`賾O5:δl6ЎMjζͺMr豷vzη=so*`a``a`0x  T ` lxajou2010D 2 10| ”| $ 2:36:28jaeho8, 0, 0, 466 WIN32LEWindows_7@m @@'@V&mfxhki&E֤C&9 ay2B4k'ٵn Ho WkQ&4X fR4A~FmAS-?Js ړC=z zyQ&iYG~3^&Y4 3WR檳џ<)Y)Q!_t)e F xX0+>(`km,eTvO5:v[h_|gKo9!ԥՄ4 ׏AX@]!zc-$pq[X2Iܻ,1Wb* %/N)vK;5v- {(=\}v;kNpUWc2՗n5kd;OWFmֆ?ӼO)i; kOtLniɛOdڙ8Yt=2N)cE{jD;aItgՎno^Y0ԗW}қH+>GgNb&b2䇓1јc1ɭ٘tk.3,x(tE1ӱGjdR} sF낼EË#SA>d:^ڸ"؊ԃriwξa)і%'I31מ/H&U)N]Y((܇-`K"c[7mпNPo/!ȢqMd6@DT}сS1q2ĉEŁӂASnۛۜk%lȝ6ev8sIkK [?e+l<+AVVr 6j>]X1c2ԣh:ʲHWP Document Filei$l p6J9{82xj]yt )4髠`1)ρoT4 նgV [-vw&5gY'\޿E#nK# t"kK [?e+l<+AVVr 6j>]X1c2ԣh:ʲHWP Document Filei$l p6J9{82xj]yt )4髠`1)ρoT4 նgV [-vw&5gY'\޿E#nK# /"u@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈nsus has emerged yet, the ideal cell type for the treatment of heart disease should: (a) improve heart function; (b) create healthy and functional cardiac muscle and vasculature, integrated into the host tissue; (c) be amenable to delivery by minimally inva>VME d!QdBč!a& ]^{vrA1J7brSSr!F͢`75=S`ycLZ`L _z[-Ķ0MFY\\GW:?ChkUm17#>'Kj!c7Ӂy*0Ҟ4խz;Ы97?>av.$'&ɷ1#z59 <CZ{kF9jo|^ÍԳ*Sc@쁳"YlK9.Kn$ꗱi7@!Y`xܘ?wg M,l:=sM>1{{\'ܚsu\iKGVy1ك &6$ 8{p6:r/Ǯ̗ׯ_! 4yj<:߀(| c/.g+c__XYWKRFaIrPкQŠռCFʃpP  k^bECyl]_ىC DžɁBewv-Y]bE8lLPW0ޣ_ 6&hR1<"8#k=`P`^1:َ!x6r0(c9z4劮.|7t%!KsV&@+rءO+<>ffG5zryvk\9o7%-V;o3h{ygR5b-?Bu+dVSv9CWc;SpZUs)c`Q)[MŢyͳy [,<9RE8[tUqݥH/ю=ts<xqj̐դ)ř;'fqZo_vYZ^Jeh{ 32EnPC*RNYUʳ9J:.lUqI IcފW[3PX+23VrtgeenU5κ*P꓃ܝ;pñ=Q|G3F6@/rLw=fw'EdN4m཯1*zWI\jDOPovrjVQPa3ړ7զ2RnѦ[O/Npr^.q(cmd@U}WOHQfvA,@a5 ]G$ ئ[nI^~A0A!U ׷ #4&s= 8OnO:p\8+ovc8/1K8Oy!6㎣l3k1_1j٘*`Ab3l:bb6:ؘ;v11bca 6 L1(ЃW#lLb|٘ ĸ1)8IJB0/`&a4sr=i<6ś_&sM IzNPGɤ\Y@w)d4cLlYˑ 526J0i|2L\؝.d_MC ,+;FM<WVLƍoucey[+kTT4cʛ⨬"dU4*|W3J}^#EԨxLHI tߕ9T,Jq4lU>s4c7) dVc+mgK/g /wXU堙yOcI ų0!96VfS)M b>8|QGgVS=IMH[KxnxBQv50J#ѓoD(' .#wCvEₕp8jMD:AXjsʖĩUKw߫ t@|/ZU7_xjFrN}G]/4 e8m cd``pq`bPyR```abb`c512UD#Q < {7`y5`Cȫ,',v)0=f'H!?'Z86gHp6nn Q;  %.˵5Ised: =D91CT7 VME dd!QdBCM.]i^{vrA1J7brSS<}uufQzU{Z2cLǧ'_zu6|đ->>(wJǷYtEi=<9W; ,>ߴʱ󤲵nΙc-}1i $-11 y[GSD%Ahn#s ;3)},pgY+y#>Ѱ12<6^MѶxP,W6ag8Ggˎ*n{Tab1ջǜnԗFZ/3eN5i ZyюY^Wj~ 8".2P(m! ^:1)E*XǺȡWc1,YկZ>yJUIuLYloZ(Lj\ 4j D^qPq **ꨁ |;hXUhhygFkťkF͎uTL]ƈAC[AZzFȍjHC E^<[cĩVH 6jk "EsJn,T,ݭYW50T\P}r9s}n8ּ=Jt ޙ(rȆV׺.W.)T-4V[Uy!+֓.Л]ZEſUwL9(-ipS"ċi#Nm$s5WOHQfvA,@a5 ]G$ ئ[nI^~ B$ $U ׷ #4&s= 8OnO:p\8+ovc8/1K8Oy!6㎣l3k1_1j٘*`Ab3l:bb6:ؘ;v11bca 6 L1(ЃW#lLb|٘ ĸ1)8IJB0/`&a4sr=i<6ś_&sM IzNPGɤ\Y@w)d4cLlYˑ 526J0i|2L\؝.d_MC ,+;FM<WVLƍoucey[+kTT4cʛ⨬"dU4*|W3J}^#EԨxLHI tߕ9T,Jq4lU>s4c7) dVc+mgK/g /wXU堙yOcI ų0!96VfS)M b>8|QGgVS=IMH[KxnxBQv50J#ѓoD(' .#wCvEₕp8jMD:AXjsʖĩUKw߫ t@|/ZU7_xjFrN}G]/4 e8m c``d``pq`bPyR```abb`c512UD#Q < {7`y5`Cȫ,',v)0=f'H!?'Z86(gHp6nn Q;  %.˵5Ised: =D91CT7 "